Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...
HER2-directed therapies, including monoclonal antibodies, ADCs, and TKIs, have improved survival in HER2-positive breast cancer patients. Clinical trials like CLEOPATRA, DESTINY-Breast01, and ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: I want you ...
Hosted on MSN
New FDA approved drug combo offers HER2-positive metastatic breast cancer patients hope
For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand name: Enhertu) in combination with pertuzumab (brand name Perjeta) is offering ...
Enhertu, a targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo, may now be used as a first-line treatment for advanced cases of breast cancer, making it the first new approved ...
Dec 15 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab Enhertu in combination with Roche's (ROG.S ...
FDA expands labels for Roche's PATHWAY HER2 (4B5) test* and VENTANA HER2 Dual ISH DNA Probe Cocktail, which can now be used to identify HER2-positive metastatic breast cancer patients that could be ...
Fam-trastuzumab deruxtecan-nki combined with pertuzumab significantly reduces disease progression risk in HER2-positive metastatic breast cancer. The DESTINY-Breast09 trial showed a median progression ...
Early and sustained clearance of circulating tumor DNA (ctDNA) was strongly associated with achieving pathologic complete response (pCR) in patients with early HER2-positive breast cancer receiving ...
Please provide your email address to receive an email when new articles are posted on . The tucatinib combination resulted in a 36% reduction in risk for disease progression or death. Median PFS was ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results